Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 14

1.

Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.

Redman BG, Esper P, Pan Q, Dunn RL, Hussain HK, Chenevert T, Brewer GJ, Merajver SD.

Clin Cancer Res. 2003 May;9(5):1666-72.

2.

Copper lowering therapy with tetrathiomolybdate as an antiangiogenic strategy in cancer.

Brewer GJ.

Curr Cancer Drug Targets. 2005 May;5(3):195-202. Review.

PMID:
15892619
3.

Cancer therapy with tetrathiomolybdate: antiangiogenesis by lowering body copper--a review.

Brewer GJ, Merajver SD.

Integr Cancer Ther. 2002 Dec;1(4):327-37. Review.

PMID:
14664727
4.

Copper deficiency as an anti-cancer strategy.

Goodman VL, Brewer GJ, Merajver SD.

Endocr Relat Cancer. 2004 Jun;11(2):255-63. Review.

5.

Soluble markers for the detection of hypoxia under antiangiogenic treatment.

Drevs J.

Anticancer Res. 2003 Mar-Apr;23(2A):1159-61. Review.

PMID:
12820365
6.

Control of copper status for cancer therapy.

Goodman VL, Brewer GJ, Merajver SD.

Curr Cancer Drug Targets. 2005 Nov;5(7):543-9. Review.

PMID:
16305350
7.

Mitoxantrone: a review of its use in multiple sclerosis.

Scott LJ, Figgitt DP.

CNS Drugs. 2004;18(6):379-96. Review.

PMID:
15089110
8.

Molecular imaging of antiangiogenic agents.

Rehman S, Jayson GC.

Oncologist. 2005 Feb;10(2):92-103. Review.

9.

Copper control as an antiangiogenic anticancer therapy: lessons from treating Wilson's disease.

Brewer GJ.

Exp Biol Med (Maywood). 2001 Jul;226(7):665-73. Review.

PMID:
11444102
10.

The use of copper-lowering therapy with tetrathiomolybdate in medicine.

Brewer GJ.

Expert Opin Investig Drugs. 2009 Jan;18(1):89-97. doi: 10.1517/13543780802621859 . Review.

PMID:
19053885
11.

The promise of copper lowering therapy with tetrathiomolybdate in the cure of cancer and in the treatment of inflammatory disease.

Brewer GJ.

J Trace Elem Med Biol. 2014 Oct;28(4):372-8. doi: 10.1016/j.jtemb.2014.07.015. Epub 2014 Aug 10. Review.

PMID:
25194954
12.

Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies.

O'Connor JP, Jackson A, Parker GJ, Roberts C, Jayson GC.

Nat Rev Clin Oncol. 2012 Feb 14;9(3):167-77. doi: 10.1038/nrclinonc.2012.2. Review.

PMID:
22330689
13.

Copper imbalances in ruminants and humans: unexpected common ground.

Suttle NF.

Adv Nutr. 2012 Sep 1;3(5):666-74. doi: 10.3945/an.112.002220. Review.

14.

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents.

O'Connor JP, Jackson A, Parker GJ, Jayson GC.

Br J Cancer. 2007 Jan 29;96(2):189-95. Epub 2007 Jan 9. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk